greeksoup/ stock research
Stock research / United States / RARE / Filings

Ultragenyx Pharmaceutical Inc. SEC filings

Ultragenyx Pharmaceutical filed 31 documents with the SEC in the last twelve months, the latest report being the 10-Q of 5 August 2026. The latest filing, on 19 October 2026, was an 8-K: other events.

Filings in twelve months3122 of them 8-K news
Latest report10-Qfiled 5 Aug 2026
Latest filing8-K19 Oct 2026
Last results, two-day move-0.4%results filed 4 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (17). Results came out 5 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 5 releases the share price moved 6.2% on average in the two days around results, the most on 12 Feb 2026 (-14.1%).

12 Jan 2026+7.1%$22.51 to $24.11
12 Feb 2026-14.1%$23.88 to $20.52
5 May 2026+4.5%$24.81 to $25.93
4 Aug 2026-0.4%$25.02 to $24.93
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

22 filings

Ultragenyx Pharmaceutical's 22 news filings (8-K) were mostly about other events (14) and results of operations (5).

  • Other eventsNews the company chose to file
    14 · latest 19 Oct 2026
  • Results of operationsThe quarterly results release
    5 · latest 4 Aug 2026
  • Material agreementA large contract or deal was signed
    3 · latest 14 Oct 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    1 · latest 18 May 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 18 May 2026
  • Exit or disposal costsCosts to close or sell part of the business
    1 · latest 12 Feb 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Ultragenyx Pharmaceutical Inc. filed 31 documents with the SEC of the kinds listed here: 22 current reports (8-K), about 14 other events; 5 results of operations; 3 material agreement; 1 officer or director change; 1 shareholder vote; 3 quarterly reports (10-Q), 2 additional proxy materials (DEFA14A), 1 employee share plan registration (S-8), 1 annual report to shareholders (ARS), 1 proxy statement (DEF 14A), 1 annual report (10-K). The latest, filed 19 October 2026: 8-K, other events. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    19 October 20268-KOther events19 October 2026EDGAR
    14 October 20268-KMaterial agreement8 October 2026EDGAR
    7 October 20268-KMaterial agreement6 October 2026EDGAR
    17 September 20268-KOther events17 September 2026EDGAR
    2 September 20268-KOther events2 September 2026EDGAR
    19 August 20268-KOther events19 August 2026EDGAR
    11 August 20268-KOther events7 August 2026EDGAR
    5 August 202610-Qquarterly report30 June 2026EDGAR
    4 August 20268-KResults of operations4 August 2026EDGAR
    12 June 2026S-8employee share plan registrationEDGAR
    18 May 20268-KOfficer or director change, Shareholder vote14 May 2026EDGAR
    6 May 202610-Qquarterly report31 March 2026EDGAR
    5 May 20268-KResults of operations5 May 2026EDGAR
    30 April 2026DEFA14Aadditional proxy materialEDGAR
    2 April 20268-KOther events2 April 2026EDGAR
    30 March 20268-KOther events30 March 2026EDGAR
    27 March 2026ARSannual report to shareholders31 December 2025EDGAR
    27 March 2026DEFA14Aadditional proxy materialEDGAR
    27 March 2026DEF 14Aproxy statement14 May 2026EDGAR
    12 March 20268-KOther events12 March 2026EDGAR
    23 February 20268-KOther events23 February 2026EDGAR
    18 February 202610-Kannual report31 December 2025EDGAR
    12 February 20268-KResults of operations, Exit or disposal costs12 February 2026EDGAR
    3 February 20268-KOther events3 February 2026EDGAR
    30 January 20268-KOther events30 January 2026EDGAR
    12 January 20268-KResults of operations12 January 2026EDGAR
    30 December 20258-KOther events30 December 2025EDGAR
    29 December 20258-KOther events29 December 2025EDGAR
    5 November 202510-Qquarterly report30 September 2025EDGAR
    4 November 20258-KMaterial agreement, Results of operations3 November 2025EDGAR
    30 October 20258-KOther events30 October 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.